Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,938 total articles
Ichor is benefitting from accelerating semiconductor capex: revenue run-rates have moved above $240m per quarter and management expects sequential growth through 2026. The stock has momentum but still trades at reasonable enterprise-value-to-sales near 2.0. I recommend a tactical long swing with strict risk control while watching margins and cash f…
ArcelorMittal (MT) has been reshaping its business into regionally run hubs with greater vertical integration and targeted sustainable capex. That structural shift should compress cyclicality, improve margins over time and support multiple expansion from trough levels. We like a tactical long at current prices with a clear stop and a mid-to-long ho…
Vertiv sits squarely in the crosshairs of the AI data center power and cooling shortage. Strong free cash flow, healthy margins and an expanding addressable market justify a bullish, mid-term swing trade, but lofty multiples and execution risk demand a tight stop and clear exit plan.
LPL Financial (LPLA) remains our preferred way to play advisor-led wealth management exposure. Continued advisor onboarding, pockets of AUM wins (including a $2.4B team), a healthy ROE, and rising rates that fatten cash yields on client balances underpin a bullish thesis. Valuation is not cheap at ~28x earnings, but operational leverage and improvi…
Alphabet is funding a massive AI buildout that has turned shareholders into backers. If Alphabet successfully commercializes its Tensor Processing Units (TPUs) and related hardware/services, the company can recover capital intensity with much higher returns on invested capital. We lay out a trade: enter at $342.06, stop at $320.00, target $420.00 o…
Zoom's equity stake in Anthropic plus deep product integration with Claude creates a direct, near-term catalyst. Fundamentals and FCF generation make a well-contained risk-reward for a swing trade. Upgrade to Buy with a clear plan: entry $95.00, stop $85.00, target $125.00 over the next 45 trading days.
EyePoint (EYPT) sold off after a disappointing readout in Lugano. The market is punishing clinical disappointment, pushing the shares toward a 52-week low, yet the company still carries roughly $223M in runway, manageable enterprise value, and ongoing Phase 3 catalysts. For traders willing to accept biotech binary risk, a controlled swing long offe…
Adyen remains a high-quality payments franchise with durable unit economics and a substantial cash balance. On a pure free-cash-flow basis the stock looks fairly valued today, but the company's net cash and recurring merchant relationships create a lower-risk asymmetric trade if you buy a controlled pullback. This trade idea outlines an actionable …
Kirby Corporation's mix of durable cash flow, low leverage and an active share repurchase program creates a favorable risk-reward setup around $139. Catalysts include continued inland market improvement, share buybacks and positive sector momentum. Trade plan: enter $139.00, stop $129.00, target $157.69 - mid-term (45 trading days).
General Motors combines strong free cash flow, a low price-to-book, and growing software and services optionality. We see a mid-term buying opportunity at $86.00 with a $95.00 target and an $80.00 stop, driven by solid FCF, a manageable valuation versus enterprise value, and several near-term catalysts—while acknowledging tariff noise, capital inte…
KLA is a high-quality, cash-generative monopoly in chip inspection and yield management. With AI-driven fab builds and advanced packaging ramps still constrained by inspection capacity, KLA stands to benefit from sustained capital intensity. Valuation looks rich on earnings but reasonable when you account for FCF generation and the firm's dominant …
Kimbell Royalty Partners (KRP) yields north of 12% today, but the more interesting trade is buying a de-risked royalty portfolio trading at single-digit free-cash-flow multiples with upside from production growth, modest leverage and active M&A review. Entry at $15.10, stop $13.50, target $21.00 over a long-term (180 trading days) horizon.
Information Services Group (III) is a small-cap sourcing advisory business with steady free cash flow, a modest dividend, and an attractive valuation on an EV/EBITDA and price-to-sales basis. Recent EPS misses and analyst downgrades have pressured the stock, but balance sheet strength, positive free cash flow ($16.95M) and a reasonable EV/EBITDA of…
Kinross is a cash-generative senior gold producer trading at a reasonable multiple with a clear path to higher free cash flow through margin improvement and shareholder returns. This trade idea targets a margin-driven re-rate toward the stock's 52-week highs—not an acceleration in growth—and lays out a concrete entry, stop and target with time hori…
Tutor Perini's Q2 momentum layered onto a record backlog and strong free cash flow profile makes a compelling risk/reward. Valuation on a cash-flow basis is reasonable, balance sheet is conservative, and index flows alongside continued infrastructure spending support upside to the $100+ level. I recommend a tactical long for swing traders with clea…
Vestas looks positioned to benefit from accelerating global wind installations and a backlog that should convert to revenue across the next 12-18 months. The trade targets a rebound in execution and margin recovery, with a clear entry at $42.00, stop at $36.00 and a $55.00 target over a 180-trading-day horizon.
Veeva combines industry-leading life-sciences cloud software with high-margin recurring revenue and strong free cash flow generation. After beating Q1 estimates and raising FY2027 guidance, the stock looks attractive for a long trade: entry $269.00, stop $240.00, target $320.00, horizon 180 trading days.
Amdocs (DOX) trades like a mature, cash-generative software company on the cusp of secular tailwinds from 5G, cloud-native OSS/BSS adoption and AI-enabled monetization. At roughly $6.7B market cap, a mid-teens P/E and a FCF yield north of 7%, the stock offers a clear value case for a long trade over the next 180 trading days—with defined entry, tar…
The Hartford Sustainable Municipal Bond Fund offers a compelling risk-reward today: attractive current yield exposure to municipal credit with an ESG tilt, plus a meaningful path to capital appreciation if the fund’s discount to NAV narrows as interest rates stabilize and demand for tax-exempt sustainable assets resumes. I recommend a tactical long…
Schaeffler is trading like a company still in free-fall while its underlying business has durable technology exposure to electrification and industrial automation. The valuation is depressed enough to justify taking a long position if management can show measurable margin stabilization and working-capital discipline. This trade lays out an entry at…
AMD has already run hard in 2026, but fundamentals still support a constructive stance. Mix of server CPU share gains, expanding AI accelerator wins and healthy free cash flow justify a medium-risk long trade. Valuation is rich, so position sizing and a clear stop are critical.
SAP has moved off its July lows and is showing constructive technical and fundamental signs that the rebound can continue. With a $259.3B market cap, a PE of 27.1, and rising short interest flows, the stock offers a tactical long opportunity. Execution risk on AI and recurring-revenue conversion remains the main watch item; the trade plan below pri…
Motorcar Parts of America (MPAA) offers an asymmetric mid-term trade: record revenue growth, inexpensive valuation (EV/EBITDA ~6.4, EV/Sales ~0.48) and a near-oversold technical profile around $11.46. I favor a disciplined long with an entry at $11.46, stop at $10.00 and a $15.00 target over the next 45 trading days, sized to limit downside.
Summit Therapeutics (SMMT) has two conflicting narratives: a legacy antibiotic program and a headline-making lung cancer BLA. With the FDA review active for ivonescimab and technicals stabilizing, the stock offers an asymmetric long opportunity. This note upgrades the rating and lays out entry, stop, targets, catalysts and the key risks that would …
Amazon is trading at a rare valuation sweet spot for the combination of scale, cash generation (despite recent FCF noise), and clear capital-allocation optionality. Buy for a long-term position with an entry at $259, a stop at $246 and a primary target of $300 within 180 trading days while watching AWS traction and cash-flow normalization.
